BCDA
BioCardia, Inc.
NASDAQ · USHealthcareBiotechnology
$0.90+9.57%
Price as of Jul 20, 2026
BCDA growth
BioCardia, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- -100.0%
- EBITDA
- +11.0%
- EBIT
- +7.5%
- EPS
- +69.0%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +53.4%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- +2.0%
- EBIT
- -3.5%
- Net income
- -3.5%
- EPS
- +57.6%
- Free cash flow
- +7.3%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.